ScholarIQanswers from OpenAlex & ORCID
Joachim R. Kalden
ResearcherPublications, citations & collaboration network
Joachim R. Kalden is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Joachim R. Kalden have?
ScholarIQindexed works
Joachim R. Kalden has 220 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Joachim R. Kalden have?
ScholarIQcitation count
Joachim R. Kalden has 19,201 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Joachim R. Kalden?
ScholarIQh-index
Joachim R. Kalden has an h-index of 51 in OpenAlex.
What is the i10-index of Joachim R. Kalden?
ScholarIQi10-index
Joachim R. Kalden has an i10-index of 113 in OpenAlex.
What is the OpenAlex record for Joachim R. Kalden?
ScholarIQopenalex
The OpenAlex for Joachim R. Kalden is on the source record.
What are the most-cited papers on Joachim R. Kalden?
ScholarIQmost cited works
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
Michael J. Elliott, Ravinder N. Maini, Marc Feldmann, Joachim R. Kalden, Christian Antoni, Josef S Smolen, Burkhard F. Leeb, F. C. Breedveld, J. D. Macfarlane, J. A. Bijl, James N. Woody
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S Smolen, Diana Davis, J. D. Macfarlane, Christian Antoni, Burkhard F. Leeb, Michael J. Elliott, James N. Woody, T Schaible, Marc Feldmann
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community
Claudio Vitali, Stefano Bombardieri, Haralampos Μ. Moutsopoulos, G. Balestrieri, W. Bencivelli, Robert M. Bernstein, K. Bjerrum, S. Braga, Joaquı́n Coll, Salvatore De Vita, Alexandros A. Drosos, Michael Ehrenfeld, P.Y. Hatron, Elaine M. Hay, David Isenberg, Anne Janin, Joachim R. Kalden, L Kater, Yrjö T. Konttinen, Peter J. Maddison, Ravinder N. Maini, R. Manthorpe, Olivier Meyer, Pierantonio Ostuni, Yvon Pennec, Jan Ulrik Prause, Andrea Richards, B Sauvezie, Morten Schiødt, Maria Elisa Sciuto, Crispian Scully, Yehuda Shoenfeld, Fotini N. Skopouli, Josef S Smolen, M L Snaith, Moshe Tishler, S Todesco, Guido Valesini, Patrick J Venables, Marie J. Wattiaux, Pierre Youinou
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Christian Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E. Fürst, Jerry A. Molitor, Edward Keystone, Dafna D. Gladman, Bernhard Manger, Siegfried Wassenberg, Ralf Weier, Daniel J. Wallace, Michael H. Weisman, Joachim R. Kalden, Josef S Smolen